CTX
The efficacy threshold for defining the Optimal Biologic Dose is at least a 30% reduction in CTX. Prior bisphosphonate and denosumab treatment could confound CTX because they reduce bone resorption. Recent fractures are excluded because th…
1 sources - 4 claims
The efficacy threshold for defining the Optimal Biologic Dose is at least a 30% reduction in CTX. Prior bisphosphonate and denosumab treatment could confound CTX because they reduce bone resorption. Recent fractures are excluded because they can elevate CTX for up to 6 months before enrolment. The MOI-A primary endpoint is the percentage change in serum CTX from baseline to week 24.